Book ChapterDOI
Experience with Daily Self-Administered Subcutaneous Erythropoietin
About:
This article is published in Contributions To Nephrology.The article was published on 1989-01-01. It has received 41 citations till now. The article focuses on the topics: Erythropoietin.read more
Citations
More filters
Journal ArticleDOI
Pharmacologic doses of recombinant human erythropoietin in the treatment of myelodysplastic syndromes [see comments]
TL;DR: These studies indicate that rhEPO can be administered safely in very high doses to patients with MDS and that 24% of these patients will respond with increased erythropoiesis.
Journal ArticleDOI
Red Blood Cell Regeneration Induced by Subcutaneous Recombinant Erythropoietin: Iron-Deficient Erythropoiesis in Iron-Replete Subjects
TL;DR: Subcutaneous rEPO is an effective stimulant of erythropoiesis in nonanemic blood donors, however, in addition to eventual depletion of iron stores, early functional iron deficiency affects response to the drug.
Journal ArticleDOI
Clinical pharmacology and economics of recombinant human erythropoietin in end-stage renal disease: the case for subcutaneous administration.
TL;DR: Pharmacokinetic simulations in conjunction with clinical correlation of the erythropoietic response suggest that the duration that the ersatz levels are maintained, and not the absolute peaks, is the primary determinant of efficacy.
Journal ArticleDOI
Effects of haemoglobin normalization on quality of life and cardiovascular parameters in end‐stage renal failure
Lawrence P. McMahon,Kim Mason,Sandford L. Skinner,Caroline M. Burge,Leanne E. Grigg,Gavin J. Becker +5 more
TL;DR: There may be a significant haemodynamic and symptomatic advantage in maintaining a physiological [Hb] in haemodialysis patients, and a substantially higher dose of epoetin is required to maintain this level.
Journal ArticleDOI
Pharmacologic doses of recombinant human erythropoietin in the treatment of myelodysplastic syndromes.
TL;DR: A randomized, placebo-controlled, double-blind trial designed to evaluate the efficacy and toxicity of high doses of recombinant human erythropoietin (rhEPO) was conducted in this article.